Organization
SWOG Statistics and Data Management Center, Seattle, WA
17 abstracts
Abstract
SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.Org: UT Health San Antonio, San Antonio, TX, The Ohio State University, Columbus, OH, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, University of Chicago Medical Center, Chicago, IL, SWOG Cancer Research Network, San Antonio, TX,
Abstract
SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).Org: University of Virginia, Charlottesville, VA, USA, Fred Hutchinson Cancer Research Center, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Levine Cancer Institute,
Abstract
Effects of immune-enhancing nutrition on radical cystectomy outcomes: Primary results from the randomized phase III double-blind clinical trial (S1600).Org: University of Kansas Medical Center, Kansas City, KS, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA,
Abstract
Cancer clinical trial participation in socioeconomically vulnerable patients: A risk model to aid in targeted interventions.Org: Arnold Ventures, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Research Center,
Abstract
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.Org: Huntsman Cancer Institute at the University of Utah, SWOG Statistics and Data Management Center, Seattle, WA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, University of Kentucky, Lexington, KY,
Abstract
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials.Org: SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Carelon Medical Benefits Management,
Abstract
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.Org: City of Hope Comprehensive Cancer Center, SWOG Statistics and Data Management Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Yale School of Medicine, Yale University,
Abstract
SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.Org: BCCancer, Multicare Auburn Medical Center, Intermountain Healthcare, Indiana University Simon Comprehensive Cancer Center, Center for Data Intensive Science at the University of Chicago,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.Org: University of Cincinnati Medical Center, SWOG Statistical Center, University of Cincinnati College of Medicine, Fred Hutchinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
The association of sociodemographic variables with smoking prevalence in patients enrolled on clinical trials.Org: City of Hope National Comprehensive Cancer Center, Duarte, CA, CanSino Biologics, SWOG Statistics and Data Management Center, Seattle, WA, Seattle Gummy Company,
Abstract
ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).Org: Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Cedars-Sinai Medical Center, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Harold C. Simmons Comprehensive Cancer Center,
Abstract
Association of measures of socioeconomic deprivation with healthcare utilization in elderly patients enrolled in SWOG cancer clinical trials.Org: Columbia University Medical Center, New York, NY, SWOG Statistics and Data Management Center, Seattle, WA, Seattle, WA, Fred Hutchinson Cancer Research Center,
Abstract
Outcomes of Black (B) versus White (W) patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (Ort): Analysis of pt-level data from SWOG-1216 phase 3 trial.Org: Huntsman Cancer Institute at the University of Utah, University of Utah/Huntsman Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, SWOG Statistics and Data Management Center, Seattle, WA, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,